Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab

wbldb

Cummings, S. R.^1,2; McCulloch, C.²

Osteoporos Int. June 2020;31(6):1019-1021

Cited Works (3)

Year	Entry
2017	Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. NEJM. October 12, 2017;377(15):1417-1427.
2018	Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD. Fracture prevention with zoledronate in older women with osteopenia. NEJM. December 20, 2018;379(25):2407-2416.
2016	Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab treatment in postmenopausal women with osteoporosis. NEJM. October 20, 2016;375(16):1532-1543.

Cited By (2)

Year	Entry
2021	Seeto AH, Abrahamsen B, Ebeling PR, Rodríguez AJ. Cardiovascular safety of denosumab across multiple indications: a systematic review and meta‐analysis of randomized trials. J Bone Miner Res. January 2021;36(1):24-40.
2021	Tominaga A, Wada K, Kato Y, Nishi H, Terayama Y, Okazaki K. Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study. Osteoporos Int. April 2021;32(4):653-661.